Novel role for CRK adaptor proteins as essential components of SRC/FAK signaling for epithelial-mesenchymal transition and colorectal cancer aggressiveness

Int J Cancer. 2020 Sep 15;147(6):1715-1731. doi: 10.1002/ijc.32955. Epub 2020 Mar 16.

Abstract

Epithelial-mesenchymal transition (EMT) is a cell plasticity process required for metastasis and chemoresistance of carcinoma cells. We report a crucial role of the signal adaptor proteins CRK and CRKL in promoting EMT and tumor aggressiveness, as well as resistance against chemotherapy in colorectal and pancreatic carcinoma. Genetic loss of either CRKL or CRK partially counteracted EMT in three independent cancer cell lines. Strikingly, complete loss of the CRK family shifted cells strongly toward the epithelial phenotype. Cells exhibited greatly increased E-cadherin and grew as large, densely packed clusters, completely lacked invasiveness and the ability to undergo EMT induced by cytokines or genetic activation of SRC. Furthermore, CRK family-deficiency significantly reduced cell survival, proliferation and chemoresistance, as well as ERK1/2 phosphorylation and c-MYC protein levels. In accordance, MYC-target gene expression was identified as novel hallmark process positively regulated by CRK family proteins. Mechanistically, CRK proteins were identified as pivotal amplifiers of SRC/FAK signaling at focal adhesions, mediated through a novel positive feedback loop depending on RAP1. Expression of the CRK family and the EMT regulator ZEB1 was significantly correlated in samples from colorectal cancer patients, especially in invasive regions. Further, high expression of CRK family genes was significantly associated with reduced survival in locally advanced colorectal cancer, as well as in pan-cancer datasets from the TCGA project. Thus, CRK family adaptor proteins are promising therapeutic targets to counteract EMT, chemoresistance, metastasis formation and minimal residual disease. As proof of concept, CRK family-mediated oncogenic signaling was successfully inhibited by a peptide-based inhibitor.

Keywords: SASH1; colorectal cancer; focal adhesion; invasion; metastasis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptor Proteins, Signal Transducing / antagonists & inhibitors
  • Adaptor Proteins, Signal Transducing / metabolism*
  • Aged
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Cell Line, Tumor
  • Colon / pathology
  • Colon / surgery
  • Colorectal Neoplasms / pathology*
  • Colorectal Neoplasms / therapy
  • Datasets as Topic
  • Drug Resistance, Neoplasm / drug effects
  • Drug Screening Assays, Antitumor
  • Epithelial-Mesenchymal Transition / drug effects
  • Epithelial-Mesenchymal Transition / physiology*
  • Female
  • Focal Adhesion Kinase 1 / metabolism
  • Focal Adhesions / pathology
  • Humans
  • Male
  • Neoplasm Invasiveness / pathology
  • Neoplasm Invasiveness / prevention & control
  • Pancreatic Neoplasms / drug therapy
  • Pancreatic Neoplasms / pathology*
  • Proto-Oncogene Proteins c-crk / antagonists & inhibitors
  • Proto-Oncogene Proteins c-crk / metabolism*
  • RNA-Seq
  • Rectum / pathology
  • Rectum / surgery
  • Signal Transduction / drug effects
  • Zinc Finger E-box-Binding Homeobox 1 / metabolism
  • src-Family Kinases / metabolism

Substances

  • Adaptor Proteins, Signal Transducing
  • Antineoplastic Agents
  • CRK protein, human
  • CRKL protein
  • Proto-Oncogene Proteins c-crk
  • ZEB1 protein, human
  • Zinc Finger E-box-Binding Homeobox 1
  • Focal Adhesion Kinase 1
  • PTK2 protein, human
  • src-Family Kinases